DAWN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DAWN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Day One Biopharmaceuticals's Enterprise Value is $885.71 Mil. Day One Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-226.98 Mil. Therefore, Day One Biopharmaceuticals's EV-to-EBIT ratio for today is -3.90.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Day One Biopharmaceuticals's Enterprise Value is $885.71 Mil. Day One Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-226.57 Mil. Therefore, Day One Biopharmaceuticals's EV-to-EBITDA ratio for today is -3.91.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Day One Biopharmaceuticals's Enterprise Value is $885.71 Mil. Day One Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Day One Biopharmaceuticals's EV-to-Revenue ratio for today is .
The historical data trend for Day One Biopharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Enterprise Value | - | - | 759.81 | 1,239.36 | 907.58 |
Day One Biopharmaceuticals Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | 666.20 | 596.17 | 662.99 | 907.58 | 1,125.83 |
For the Biotechnology subindustry, Day One Biopharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Day One Biopharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1273.51566 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.408 | + | 0 | - | 366.347 |
= | 907.58 |
Day One Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1443.471344 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.3 | + | 0 | - | 317.944 |
= | 1,125.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (NAS:DAWN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Day One Biopharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 885.714 | / | -226.976 | |
= | -3.90 |
Day One Biopharmaceuticals's current Enterprise Value is $885.71 Mil.
Day One Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-226.98 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Day One Biopharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 885.714 | / | -226.566 | |
= | -3.91 |
Day One Biopharmaceuticals's current Enterprise Value is $885.71 Mil.
Day One Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-226.57 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Day One Biopharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 885.714 | / | 0 | |
= |
Day One Biopharmaceuticals's current Enterprise Value is $885.71 Mil.
Day One Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
York Charles N Ii | officer: COO, CFO and Secretary | 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746 |
Samuel C. Blackman | officer: Chief Medical Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Jeremy Bender | director, officer: Chief Executive Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Ai Day 1 Llc | 10 percent owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Julie Papanek Grant | director | 2765 SAND HILL ROAD, MENLO PARK CA 94025 |
Canaan Xi L.p. | 10 percent owner | 2765 SAND HILL RD, MENLO PARK CA 94025 |
Garry A Nicholson | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Michael Gladstone | director | 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Takeda Ventures, Inc. | 10 percent owner | 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
John A. Josey | director | C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 06-04-2023
By GlobeNewswire GlobeNewswire • 01-08-2023
By Value_Insider Value_Insider • 10-17-2022
By GlobeNewswire GlobeNewswire • 06-07-2023
By Marketwired • 09-11-2023
By GuruFocus Research GuruFocus Editor • 05-18-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 08-07-2023
By Marketwired • 08-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.